Sutro Works Toward A Better Ovarian Cancer ADC

Readies Next Asset For The Clinic

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Sutro Biopharma CEO Bill Newell spoke with Scrip about the company’s novel platform, its goal of improving folate receptor alpha-driven ovarian cancer and its business development strategy.

Sutro Biopharma sign, logo on headquarters facade of an American public biotechnology company. - South San Francisco, California,
• Source: Shutterstock

Sutro Biopharma, Inc. chose to focus its cell-free protein synthesis technology platform on antibody-drug conjugates (ADCs) long before ADCs were elevated to high-value status in recent years, and the company has used business development strategically to raise funding for its wholly owned development programs and to advance its XpressCF platform. Now, its lead ADC candidate luveltamab tazevibulin (luvelta) is in a pivotal trial to see if Sutro can deliver a better ovarian cancer option.

Key Takeaways

  • Sutro has taken lead product candidate luvelta into a pivotal trial in ovarian cancer in an increasingly competitive space – FRα-targeting ADCs.

Scrip spoke with CEO Bill Newell at the recent BIO International Convention about luvelta’s ongoing Phase II/III REFRαME-01 clinical trial,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from BIO

Sutro Works Toward A Better Ovarian Cancer ADC

 
• By Mandy Jackson

Sutro Biopharma CEO Bill Newell spoke with Scrip about the company’s novel platform, its goal of improving folate receptor alpha-driven ovarian cancer and its business development strategy.

Amgen’s Ian Thompson On Payer Shifts, Obesity Opportunity And The Future Of Blockbusters

 
• By Mandy Jackson

Scrip spoke with Amgen’s senior VP of US business operations about the impact of drug pricing and reimbursement pressures coming from government policy changes and commercial payers.

Competitive Dealmaking Market Shifts To Smaller M&A, Partnering

 
• By Mandy Jackson

Dollars spent on biopharma M&A so far in 2024 may not be as high as in 2023, but dealmakers say deal volume is robust with many factors influencing the overall value of transactions this year.

Finance Watch: Lilly’s Gateway Labs, Deerfield’s Cure Offer Biotechs Space To Grow

 
• By Mandy Jackson

Private Company Edition: Scrip spoke with the leaders of Gateway Labs and Cure at the BIO International Convention about their mini ecosystems. Also, radiopharmaceutical firm ITM raised €188m ($201.9m), Santa Ana Bio emerged with $168m and Alzheon’s series E totaled $100m.

More from Conferences

ESMO 24: NIAGARA – Trial Design Question Hangs Over Imfinzi’s Bladder Cancer Return

 
• By Alexandra Shimmings

AstraZeneca’s NIAGARA trial of perioperative Imfinzi in bladder cancer was positively received at the ESMO meeting but its design did not distinguish the contributions of each treatment portion to the overall effect – something that the US FDA is likely to have a view on.    

ESMO 24: Incyte’s Zynyz Finally Mounts The POD1UM

 
• By Alexandra Shimmings

Persistence has paid off for Incyte’s Zynyz in anal cancer with a Phase III win that should make up for a previous disappointment at the FDA and give a boost to the firm’s pipeline prospects for a post-Jakafi era.    

Sutro Works Toward A Better Ovarian Cancer ADC

 
• By Mandy Jackson

Sutro Biopharma CEO Bill Newell spoke with Scrip about the company’s novel platform, its goal of improving folate receptor alpha-driven ovarian cancer and its business development strategy.